The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy
Open Access
- 6 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Acta Neuropathologica Communications
- Vol. 9 (1), 1-17
- https://doi.org/10.1186/s40478-020-01106-1
Abstract
During the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin protein following treatment. However, the low levels of the induced dystrophin protein have raised questions on its functionality. In our present study, using an unbiased, high-throughput digital image analysis platform, we assessed markers of regeneration and levels of dystrophin associated protein via immunofluorescent analysis of whole muscle sections in 25 DMD boys who received 48-weeks treatment with exon 53 skipping morpholino antisense oligonucleotide (PMO) golodirsen. We demonstrate that the de novo dystrophin induced by exon skipping with PMO golodirsen is capable of conferring a histological benefit in treated patients with an increase in dystrophin associated proteins at the dystrophin positive regions of the sarcolemma in post-treatment biopsies. Although 48 weeks treatment with golodirsen did not result in a significant change in the levels of fetal/developmental myosins for the entire cohort, there was a significant negative correlation between the amount of dystrophin and levels of regeneration observed in different biopsy samples. Our results provide, for the first time, evidence of functionality of induced dystrophin following successful therapeutic intervention in the human.Funding Information
- Sarepta Therapeutics, Inc (HEALTH-F4-2012-30537)
- Cancer Research UK (Cl 15121 A20256)
This publication has 47 references indexed in Scilit:
- Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double‐knockout miceThe FASEB Journal, 2013
- The Effects of Low Levels of Dystrophin on Mouse Muscle Function and PathologyPLOS ONE, 2012
- Restoration of the Dystrophin-associated Glycoprotein Complex After Exon Skipping Therapy in Duchenne Muscular DystrophyMolecular Therapy, 2012
- Evidence‐based path to newborn screening for duchenne muscular dystrophyAnnals of Neurology, 2012
- Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trialsBrain, 2011
- The Dystrophin-Glycoprotein Complex in the Prevention of Muscle DamageJournal of Biomedicine and Biotechnology, 2011
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- Chronic Systemic Therapy With Low-dose Morpholino Oligomers Ameliorates the Pathology and Normalizes Locomotor Behavior in mdx MiceMolecular Therapy, 2011
- Physiological Characterization of Muscle Strength With Variable Levels of Dystrophin Restoration in mdx Mice Following Local Antisense TherapyMolecular Therapy, 2011
- Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin ProteinThe American Journal of Pathology, 2008